Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study.
about
Efficacy and safety of benzalkonium chloride-free fixed-dose combination of latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension.Conjunctival goblet cells density and preservative-free tafluprost therapy for glaucoma: an in vivo confocal microscopy and impression cytology study.A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components.Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost.Glaucoma management: relative value and place in therapy of available drug treatments.Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension.A 1-year randomized study of the clinical and confocal effects of tafluprost and latanoprost in newly diagnosed glaucoma patients.Initial Treatment: Prostaglandin Analog or Selective Laser TrabeculoplastyTopical prostaglandin analogues and conjunctival inflammation in uveitic glaucomaBenefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trialsPreservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension.Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma.Incidence of deepening of upper eyelid sulcus after topical use of tafluprost ophthalmic solution in Japanese patientsBimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trialPersonalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization.Medical treatment of glaucoma: present and future.Tafluprost: a novel prostaglandin analog for treatment of glaucoma.Tafluprost for glaucoma.Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma.Ocular surface cytotoxicity and safety evaluation of tafluprost, a recently developed anti-glaucoma prostaglandin analog.Efficacy and safety of tafluprost 0.0015% and timolol maleate 0.5% fixed combination in patients with ocular hypertension or open-angle glaucoma.Latanoprost in the treatment of glaucoma.Safety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucoma.Preservative-free tafluprost/timolol fixed combination: a new opportunity in the treatment of glaucoma.Tafluprost Ophthalmic Solution 0.0015 %: A Review in Glaucoma and Ocular Hypertension.The cytotoxic effects of preserved and preservative-free prostaglandin analogs on human corneal and conjunctival epithelium in vitro and the distribution of benzalkonium chloride homologs in ocular surface tissues in vivo.Does the intraocular pressure-lowering effect of prostaglandin analogues continue over the long term?First experience with BAK-free travoprost 0.004% in topical glaucoma medicationTafluprost for the reduction of interocular pressure in open angle glaucoma and ocular hypertension.Changes in Ocular Surface Characteristics after Switching from Benzalkonium Chloride-Preserved Latanoprost to Preservative-Free Tafluprost or Benzalkonium Chloride-Preserved Tafluprost.Analysis of the effects of preservative-free tafluprost on the tear proteome.Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension.Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma.Intraocular pressure dynamics with prostaglandin analogs: a clinical application of the water-drinking test.Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety.Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension.Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages.Efficacy and ocular surface tolerability of preservative-free tafluprost 0.0015%: a 6-month, single-blind, observational study on naïve ocular hypertension or glaucoma patients.Effect of preservative-free tafluprost on intraocular pressure, pupil diameter, and anterior segment structures in normal canine eyes.
P2860
Q33857744-C0C8AE0C-2748-4D84-9800-E943B11B2ED2Q34439352-E6F5F433-8398-4DA8-B67E-65A3EF301E66Q34678488-D248C6B0-56C2-4A08-86BE-77AF4E1F7E5DQ34737181-9F3F6992-6DD1-432A-B898-86DB6558D123Q35015841-2A816C35-8F0B-4E53-835B-90187185B1FCQ35079342-B4933F1D-E639-44AB-93E5-125D4DAB4D8AQ35237431-0965F3C1-C782-426C-A74F-4477A796D063Q35558210-A6A767F7-26E6-4910-BDB0-ACE96CB28614Q35964378-D1ACAFBA-CE8E-4939-B3E3-E8F10874FB92Q36192495-FF157C83-258A-4E86-9036-B96A09077567Q36710059-C79E928A-5C45-4E2E-B933-D5B35448E558Q36873329-904191E4-498B-405F-B427-81BCAB45C07AQ37014469-8F9F07F7-B9C1-450A-AE33-FAE3049910F3Q37027652-748AE74D-38B7-4435-BC9D-EE806176D9D2Q37030839-F8A51997-CECD-4B39-B6FB-6DF518E8C53AQ37627442-28D0CB2F-FC8E-4D0A-9EE2-FDE66D411BC1Q37870933-D7094F1E-99D8-4350-B928-15CC0B94F4A3Q37920765-211107EA-A088-47E0-BA45-85847FD25F3EQ37931967-1AFB9A51-45EC-4404-BA6C-4EAEF5006845Q38072028-FF5C101F-FADF-4D75-88BD-1B37872A7ED9Q38190054-F467B551-415C-4CA2-9871-37174472170AQ38244537-7A9E1015-C908-40C7-B513-F4DB0742C490Q38261310-E3B151AE-4AFC-4B5D-AD7A-D86A546464A8Q38339962-750D77BF-964B-4CA0-B771-6D959BDDEF56Q38819721-D6F690E2-A2B7-40EF-BBD8-DEAF2B0BA39AQ38844472-44EA80F1-5AF9-400F-8923-32C9DED86F9BQ39448716-5A27E801-8F54-4BBD-8195-F7AF0739A7D8Q39506959-193A9B8D-1CB7-46D1-A262-A2CEF84C8467Q40427995-1273B824-B563-44CC-A819-D2205576C0C0Q40938971-05018F8C-FC64-4356-B93D-5D598EEA98E9Q41431150-027394EB-AE69-4195-B425-9468ADDA7AAAQ41668980-0BE342F5-2DB2-4038-8BDD-246BDC827D53Q41911324-D79A7A44-10C9-43AE-9623-620BDB5CE3BDQ42181227-27EADABB-5FCE-4BEC-B062-6B41A6190D6AQ42389019-E0DE7187-240E-40F9-99B4-B686A8F66B55Q42647710-5DB6DB57-4D13-4887-B9E7-E970453A3B9AQ45375394-5A3FFCF3-9E05-4B51-8542-ADD6145D693AQ47381165-8B2E4693-3602-4387-B295-CC429CCB8C6CQ48429820-348696EC-97C5-4AFF-BA6B-24BD5261F4A2Q53177725-CBF22ADD-AF1B-4ADD-965C-5DBDD49BE555
P2860
Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Efficacy and safety of taflupr ...... double-masked phase III study.
@en
Efficacy and safety of taflupr ...... double-masked phase III study.
@nl
type
label
Efficacy and safety of taflupr ...... double-masked phase III study.
@en
Efficacy and safety of taflupr ...... double-masked phase III study.
@nl
prefLabel
Efficacy and safety of taflupr ...... double-masked phase III study.
@en
Efficacy and safety of taflupr ...... double-masked phase III study.
@nl
P2093
P2860
P1433
P1476
Efficacy and safety of taflupr ...... double-masked phase III study.
@en
P2093
Lutz E Pillunat
Phase III Study Investigators
P2860
P356
10.1111/J.1755-3768.2010.01862.X
P577
2010-02-01T00:00:00Z